An update on the STARS and NEPTUNE studies of OV101 currently ongoing in patients with Angelman syndrome.

BIOGRAPHY
Amit Rakhit, M.D., MBA, Ovid Therapeutics
As President of Ovid Therapeutics, Amit oversees the research, development, manufacturing and commercial teams. He is a senior healthcare executive with over 20 years’ experience in clinical practice and the biopharmaceutical industry. He is particularly interested in patient insights and creating innovative bridges between the biotech industry, health technology, and patient community to build better capabilities that meet the needs of patients and their caregivers. Amit has held leadership roles across various geographies and therapeutic areas. Prior to Ovid, he was Senior Vice President and Head of Worldwide Medical at Biogen, Inc. where he led the medical function for marketed and pipeline compounds in disease areas such as Multiple Sclerosis, neurodegenerative diseases and hemophilia. Amit received his B.A. in molecular cell biology from the University of California, Berkeley, his M.D. from Tufts University School of Medicine, his M.S. from Vanderbilt University School of Medicine, and MBA from Columbia Business School. He completed his fellowship in pediatric cardiology and was subsequently on staff at The Children’s Hospital, Boston affiliated with Harvard University.

свернуть